Loperamide 2mg capsules

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

Buy It Now

Active ingredient:
Loperamide hydrochloride
Available from:
Milpharm Ltd
ATC code:
A07DA03
INN (International Name):
Loperamide hydrochloride
Dosage:
2mg
Pharmaceutical form:
Capsule
Administration route:
Oral
Class:
No Controlled Drug Status
Prescription type:
Valid as a prescribable product
Product summary:
BNF: 01040200; GTIN: 08901175040704
Authorization number:
PL 16363/0534

Read the complete document

Package leaflet:

Information for the user

Loperamide 2 mg

Hard Capsules

loperamide

hydrochloride

Read all of this leaflet carefully

before you start taking this

medicine because it contains

important information for you.

-

Keep this leaflet. You may

need to read it again.

-

If you have any further

questions, ask your doctor

or pharmacist.

This medicine has been

prescribed for you only.

Do not pass it on to others.

It may harm them, even if

their signs of illness are the

same as yours.

If you get any side effects, talk

to your doctor or pharmacist.

This includes any possible

side effects not listed in this

leaflet. See section 4.

What is in this leaflet

1.

What Loperamide is and

what it is used for

What you need to know

before you take Loperamide

How to take Loperamide

Possible side effects

How to store Loperamide

Contents of the pack and

other information

1. What Loperamide is and

what it is used for

This medicine contains

Loperamide which helps to stop

diarrhoea by making the stools

more solid and less frequent.

This medicine is used for the

treatment of sudden short-lived

(acute) attacks of diarrhoea in

adults and children over 12 years

of age.

Please note that this medicine

only relieves the symptoms of

diarrhoea and it is important

to drink sufficient fluid to

replace the water lost in the

loose stools.

2.

What you need to know

before you take

Loperamide

Do not take Loperamide:

You are allergic to loperamide

or to any of the other

ingredients in this medicine

(listed in section 6).

You suffer from colitis

(inflammation of the colon)

or any other inflammatory

bowel disease, such as

ulcerative colitis.

You have severe diarrhoea

after taking antibiotics.

You have a swollen stomach

or tummy, and/or constipation.

-

You are suffering from acute

dysentery the symptoms of

which may include blood

in your stools and a high

temperature.

if it is for a child aged below 12

If any of these apply to you,

get advice from a doctor or

pharmacist.

Warnings and precautions

Talk to your doctor or pharmacist

before taking Loperamide

If you have AIDS and your

stomach becomes swollen.

Stop taking the capsules

immediately and contact

your doctor.

If you suffer from liver

problems.

If you have severe diarrhoea

as your body loses more fluid,

sugars and salts than normal.

If your diarrhoea lasts for

more than 48 hours stop

taking the capsules and

consult your doctor.

If you develop a bowel

obstruction stop taking the

capsules and consult your

doctor.

If you have an intolerance

to some sugars, unless

your doctor tells you to (this

medicine contains lactose)

Do not take this product for

anything other than its intended

use (see section 1) and never

take more than the recommended

amount (see section 3). Serious

heart problems (symptoms of

which include fast or irregular

heartbeat) have been reported

in patients who have taken too

much loperamide, the active

ingredient in Loperamide.

Children

Not recommended for children

under 12 years of age.

Other medicines and Loperamide

Tell your doctor or pharmacist if

you are taking, have recently taken

or might take any other medicines.

-

ritonavir (used to treat HIV).

quinidine (used to treat

abnormal heart rhythms or

malaria).

oral desmopressin (used to

treat excessive urination).

Itraconazole or ketoconazole

(used to treat fungal infections).

gemfibrozil (used to treat high

levels of lipids in the blood).

anti-cholinergic drugs

Consult a doctor before taking

Loperamide if you use any of the

above mentioned medicines.

Loperamide with food and drink

You can take Loperamide with

food and drink.

Pregnancy, breast-feeding and

fertility

If you are pregnant or breast-

feeding, think you may be

pregnant or are planning to

have a baby, ask your doctor

or pharmacist for advice before

taking this medicine.

Do not take this medicine if

you are breastfeeding as small

amounts may get into your milk.

Talk to your doctor about a

suitable treatment.

Driving and using machines

This medicine may make you feel

dizzy, tired or sleepy. You may

also lose consciousness, feel

faint or less alert. If affected do

not drive or operate machinery.

Loperamide 2 mg Hard

Capsules contains lactose

If you have been told by

your doctor that you have an

intolerance to some sugars,

contact your doctor before taking

this medicinal product.

3.

How to take Loperamide

Always take this medicine exactly

as your doctor or pharmacist has

told you. Check with your doctor

or pharmacist if you are not sure.

Adults, the elderly and

children over 12 years

How to take:

The capsules should be

swallowed whole with a drink

of water.

Dose and how often to take:

After the first loose stool (bowel

motion) take 2 capsules with

water.

After each further loose stool,

take 1 capsule.

Rehydration sachets are

available separately.

Do not give to children

under 12 years of age.

Do not take more than

6 capsules in any 24 hours.

If symptoms persist for

more than 48 hours, stop

taking the capsules and

consult your doctor.

Replace lost fluid by drinking

more liquid than usual.

DO NOT EXCEED THE

STATED DOSE.

P1519772

If you take more

Loperamide than you

should

Contact your doctor or

nearest Accident and

Emergency department

(Casualty) taking

this leaflet with you.

If you have taken too many

Loperamide, immediately

contact a doctor or hospital for

advice. Symptoms may include:

increased heart rate, irregular

heartbeat, changes to your

heartbeat (these symptoms

can have potentially serious,

life-threatening consequences),

muscle stiffness, uncoordinated

movements, drowsiness,

contraction of the pupil, difficulty

urinating, or weak breathing,

fainting.

Children react more strongly to

large amounts of Loperamide

than adults. If a child takes

too much or shows any of the

above symptoms, call a doctor

immediately.

If you forget to take

Loperamide

You should only take this

medicine as required following

the dosage instructions carefully.

If you forget to take a dose, take

a dose after the next loose stool

(bowel movement). Do not take

a double dose to make up for a

forgotten dose.

If you have any further questions

on the use of this medicine, ask

your doctor or pharmacist.

4.

Possible side effects

Like all medicines, this medicine

can cause side effects, although

not everybody gets them.

If any of the side effects gets

serious, or if you notice any

side effects not listed in this

leaflet, please tell your doctor

or pharmacist.

If you experience any of the

following stop using the

medicine and seek immediate

medical help: Rare: may affect

up to 1 in 1,000 people

-

Allergic reactions including

unexplained wheezing,

shortness of breath, swelling

of the face and throat

Loss of consciousness

or reduced level of

consciousness (feeling faint

or less alert)

Skin rashes which may be

severe and include blistering

and peeling of the skin.

Other side effects

If you experience any of the

following stop taking the

medicine and talk to your

doctor:

Common: may affect up to 1 in

10 people

-

Headache, dizziness

-

Nausea (feeling sick),

constipation, flatulence (wind).

Uncommon: may affect up to

1 in 100 people

-

Tiredness, drowsiness

Stomach pains, vomiting,

indigestion and heartburn,

dry mouth.

Rash

Rare: may affect up to

1 in 1000 people

Itchiness or hives

Constriction of the pupil

Difficulty passing water (urine)

A swollen stomach, a burning

sensation in the mouth,

lips or tongue

Fatigue.

Reporting of side effects

If you get any side effects, talk

to your doctor, pharmacist or

nurse. This includes any possible

side effects not listed in this

leaflet. You can also report side

effects directly via the national

reporting system listed in

Yellow Card Scheme, Website:

www.mhra.gov.uk/yellowcard.

By reporting side effects, you can

help provide more information

on the safety of this medicine.

5.

How to store Loperamide

Keep this medicine out of the

sight and reach of children.

Do not use this medicine after

the expiry date which is stated on

the carton after EXP. The expiry

date refers to the last day of that

month.

Store below 30°C.

Do not throw away any medicines

via wastewater or household

waste. Ask your pharmacist how

to throw away medicines you no

longer use. These measures will

help protect the environment.

6.

Contents of the pack and

other information

What Loperamide contains

The active substances is

loperamide hydrochloride.

Each hard capsule contains 2 mg

of loperamide hydrochloride.

The other ingredients are:

Capsules content: Lactose

monohydrate, maize starch, talc,

magnesium stearate.

Capsules shell: Titanium dioxide

(E171), gelatin.

Printing Ink: Shellac, black iron

oxide (E172).

What Loperamide looks like

and contents of the pack

Hard Capsule.

White opaque cap/White opaque

body, size ‘4’ hard gelatin capsule

shells, imprinted with ‘2’on cap

and ‘L’ on body with black ink

filled with white to off-white

powder.

Loperamide hard capsules are

available in clear PVC/Aluminium

blisters pack.

Pack sizes:

Blister packs: 6, 8, 10, 12, 15, 18,

20, 30 & 50 hard capsules.

Not all pack sizes may be

marketed.

Marketing Authorisation Holder

Milpharm Limited

Ares Block,

Odyssey Business Park,

West End Road

South Ruislip HA46QD

United Kingdom

Manufacturer

APL Swift Services (Malta) Limited

HF26, Hal Far Industrial Estate,

Hal Far

Birzebbugia, BBG 3000

Malta

Milpharm Limited

Ares Block,

Odyssey Business Park,

West End Road

South Ruislip, HA46QD

United Kingdom

Generis Farmaceutica, S.A.

Rua Joao de Deus

19, 2700-487 Amadora

Portugal

This leaflet was last revised

in 04/2018.

P1519772

Read the complete document

Object 1

Loperamide 2mg Capsules

Summary of Product Characteristics Updated 24-Sep-2019 | Aurobindo Pharma - Milpharm Ltd.

1. Name of the medicinal product

2. Qualitative and quantitative composition

3. Pharmaceutical form

4. Clinical particulars

4.1 Therapeutic indications

4.2 Posology and method of administration

4.3 Contraindications

4.4 Special warnings and precautions for use

4.5 Interaction with other medicinal products and other forms of interaction

4.6 Fertility, pregnancy and lactation

4.7 Effects on ability to drive and use machines

4.8 Undesirable effects

4.9 Overdose

5. Pharmacological properties

5.1 Pharmacodynamic properties

5.2 Pharmacokinetic properties

5.3 Preclinical safety data

6. Pharmaceutical particulars

6.1 List of excipients

6.2 Incompatibilities

6.3 Shelf life

6.4 Special precautions for storage

6.5 Nature and contents of container

6.6 Special precautions for disposal and other handling

7. Marketing authorisation holder

8. Marketing authorisation number(s)

9. Date of first authorisation/renewal of the authorisation

10. Date of revision of the text

1. Name of the medicinal product

Loperamide 2 mg Hard Capsules

2. Qualitative and quantitative composition

Each hard capsule contains 2 mg of loperamide hydrochloride.

Excipient with known effect:

Each hard capsule contains 144.6 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Hard capsule,

White opaque cap/White opaque body, size '4' hard gelatin capsule shells, imprinted with '2'on cap and 'L'

on body with black ink filled with white to off-white powder.

4. Clinical particulars

4.1 Therapeutic indications

For symptomatic treatment of acute diarrhoea in adults and children aged 12 years and over.

4.2 Posology and method of administration

Posology

Adults and children over 12 years of age:

Two capsules to be taken initially, followed by one capsule after each loose motion, up to a maximum of

six capsules in any 24 hours.

Children under 12 years of age:

Not recommended

Use in Elderly

No dose adjustment is required for the elderly.

Renal impairment

No dose adjustment is required for patients with renal impairment.

Hepatic impairment

Although no pharmacokinetic data are available in patients with hepatic impairment Loperamide should

be used with caution in such patients because of reduced first pass metabolism (see section 4.4 Special

warnings and precautions for use).

Method of administration

Oral use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipient listed in section 6.1.

When inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including

ileus, megacolon, toxic megacolon and certain poisonings in particular:

Children less than 12 years of age.

When ileus or constipation are present or when abdominal distension develops

In patients with acute ulcerative colitis.

In patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and

Campylobacter.

In patients with pseudomembranous colitis associated with the use of broad- spectrum antibiotics.

Loperamide hydrochloride should not be used alone in acute dysentery, which is characterised by blood

in stools and elevated body temperatures.

4.4 Special warnings and precautions for use

Treatment of diarrhoea with loperamide is only symptomatic. Whenever an underlying etiology can be

determined, specific treatment should be given when appropriate.

The priority in acute diarrhoea is the prevention or reversal of fluid and electrolyte depletion. This is

particularly important in young children and in frail and elderly patients with acute diarrhoea. Use of

loperamide hydrochloride does not preclude the administration of appropriate fluid and electrolyte

replacement therapy.

Since persistent diarrhoea can be an indicator of potentially more serious conditions, loperamide

hydrochloride should not be used for prolonged periods until the underlying cause of the diarrhoea has

been investigated.

Loperamide hydrochloride must be used with caution when the hepatic function necessary for the drug's

metabolism is defective (eg in cases of severe hepatic disturbance), as this might result in a relative

overdose leading to CNS toxicity

Patients with AIDS treated with loperamide hydrochloride for diarrhoea should have therapy stopped at

the earliest signs of abdominal distension. There have been isolated reports of toxic megacolon in AIDS

patients with infectious colitis from both viral and bacterial pathogens treated with loperamide

hydrochloride.

When no clinical change is observed in the acute diarrhoea within 48 hours, the administration of

loperamide must be interrupted and the patient must be advised to consult his doctor.

Treatment with Loperamide must be interrupted immediately when obstipation, abdomnial distension or

subileus develops

Cardiac events including QT prolongation and torsades de pointes have been reported in association with

overdose. Some cases had a fatal outcome (see section 4.9). Overdose can unmask existing Brugada

syndrome. Patients should not exceed the recommended dose and/or the recommended duration of

treatment.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-

galactose malabsorption should not take this medicine because it contains lactose.

4.5 Interaction with other medicinal products and other forms of interaction

Non-clinical data have shown that loperamide is a P-glycoprotein substrate. Furthermore, loperamide is

mainly metabolised by CYP3A4 and CYP2C8.Concomitant administration of loperamide (16 mg single

dose) with quinidine, or ritonavir, which are both P-glycoprotein inhibitors, resulted in a 2 to 3-fold

increase in loperamide plasma levels.

The results of one published pharmacokinetic study suggested that the concomitant administration of

loperamide with oral desmopressin may result in a 3-fold increase of desmopressin plasma concentrations

although no clinical effects were reported.

Possible interactions may occur with drugs that delay intestinal peristalsis (for instance anti-cholinergic

drugs) because the effects of loperamide could be enhanced.

Administration of itraconazole with loperamide (4 mg single dose) increased loperamide plasma levels 3-

to 4-fold. In addition, gemfibrozil, a CYP2C8 inhibitor, increased the AUC of loperamide 2-fold.

Concomitant use of itraconazole and gemfibrozil with loperamide raised the mean Cmax and AUC of

loperamide about 2- and 13-fold, respectively. This increase did not lead to measurable CNS effects.

The concomitant administration of loperamide (16mg single dose) and ketoconazole, an inhibitor of

CYP3A4 and p-glycoprotein, resulted in a 5-fold increase in loperamide plasma concentrations. This

increase was not associated with increased pharmacodynamic effects as measured by pupillometry.

The clinical relevance of these pharmacokinetic interactions, when loperamide is given at recommended

dosages (2 mg, up to 12 mg maximum daily dose), is unknown.

4.6 Fertility, pregnancy and lactation

Pregnancy

A limited amount of data from the use of loperamide in pregnant women is available. In one of two

epidemiological studies the use of loperamide during early pregnancy suggested a possible moderate

increased risk for hypospadia, however, an increased risk for major malformations could not be identified.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see

section 5.3). Safety in human pregnancy has not been established, although from animal studies there are

no indications that loperamide HCl possesses any teratogenic or embryotoxic properties.

If possible the use of loperamide should be avoided during the first trimester of pregnancy, however, it

may be used during the second and third trimester of pregnancy

Breast-feeding

Small amounts of loperamide may appear in human breast milk. Therefore, this medicine is not

recommended during breast-feeding. Women who are pregnant or breast feeding infants should therefore

be advised to consult their doctor for appropriate treatment.

Fertility

Only high doses of loperamide hydrochloride affected female fertility in non-clinical studies (see section

5.3).

4.7 Effects on ability to drive and use machines

Loperamide hydrochloride has moderate influence on the ability to drive and use machines. Loss of

consciousness, depressed level of consciousness, tiredness, dizziness or drowsiness may occur when

diarrhoea is treated with loperamide hydrochloride.

Therefore, it is advisable to use caution when driving or operating machinery. (See section 4.8

Undesirable effects).

4.8 Undesirable effects

Adults and children aged ≥ 12 years

The safety of loperamide hydrochloride was evaluated in 2755 adults and children aged ≥ 12 years who

participated in 26 controlled and uncontrolled clinical trials of loperamide hydrochoride used for the

treatment of acute diarrhoea.

The most commonly reported (i.e. ≥1% incidence) adverse drug reactions (ADRs) in clinical trials with

loperamide hydrochoride in acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache

(1.2%) and nausea (1.1%).

Table 1 displays ADRs that have been reported with the use of loperamide hydrochoride from either

clinical trial (acute diarrhoea) or post-marketing experience.

The frequency categories use the following convention: very common (≥1/10); common (≥1/100 to

<1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); and very rare (<1/10,000).

Table 1 Adverse Drug reactions

System Organ Class

Indication

Common

Uncommon

Rare

Immune System Disorders

Hypersensitivity reaction

Anaphylactic reaction

(including Anaphylactic

shock)

Anaphylactoid reaction

Nervous System Disorders

Headache

Dizziness

Somnolence

Loss of consciousness

Stupor

Depressed level of

consciousness

Hypertonia

Coordination

abnormality

Eye Disorders

Miosis

Gastrointestinal Disorders

Constipation

Nausea

Flatulence

Abdominal pain

Abdominal discomfort

Dry mouth

Abdominal pain upper

Vomiting

Dyspepsia

Ileus

(including paralytic

ileus)

Megacolon

(including

toxic megacolon

Glossodynia

Abdominal distension

Skin and Subcutaneous

Tissue Disorders

Rash

Bullous eruption

(including Stevens-

Johnson syndrome, toxic

epidermal necrolysis and

erythema multiforme)

Angioedema

Urticaria

Pruritus

Renal and Urinary

Disorders

Urinary retention

General Disorders and

Administration Site

Conditions

Fatigue

a: Inclusion of this term is based on post-marketing reports for loperamide hydrochoride. As the process

for determining post marketing ADRs did not differentiate between chronic and acute indications or

adults and children, the frequency is estimated from all clinical trials with loperamide hydrochoride (acute

and chronic), including trials in children ≤ 12 years (N=3683).

b: See section 4.4 Special Warnings and Special Precautions for use.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows

continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are

asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard.

4.9 Overdose

Symptoms

In case of overdose (including relative overdose due to hepatic dysfunction), CNS depression (stupor,

coordination abnormality, somnolence, miosis, muscular hypertonia, and respiratory depression), urinary

retention and ileus may occur. Children may be more sensitive to CNS effects than adults.

In individuals who have ingested overdoses of loperamide HCl, cardiac events such as QT interval

prolongation, torsades de pointes, other serious ventricular arrhythmias, cardiac arrest and syncope have

been observed (see section 4.4). Fatal cases have also been reported. Overdose can unmask existing

Brugada syndrome.

Treatment

If symptoms of overdose occur, naloxone can be given as an antidote. Since the duration of action of

loperamide is longer than that of naloxone (1 to 3 hours), repeated treatment with naloxone might be

indicated. Therefore, the patient should be monitored closely for at least 48 hours in order to detect

possible CNS depression.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic Group: Antipropulsives;

ATC code: A07DA03

Loperamide hydrochloride is a synthetic opioid which inhibits gut motility by binding to opiate receptors

in the gut wall and may also reduce gastrointestinal secretions, resulting in improvement in diarrhoea

symptoms.

Loperamide also increases the tone of the anal sphincter. Onset of antidiarrhoeal effect occurred as soon

as one hour after intake of a 4 mg dose of loperamide.

In a double blind randomised clinical trial in 56 patients with acute diarrhoea receiving loperamide, onset

of anti-diarrhoeal action was observed within one hour following a single 4 mg dose. Clinical

comparisons with other antidiarrhoeal drugs confirmed this exceptionally rapid onset of action of

loperamide.

5.2 Pharmacokinetic properties

Absorption: Most ingested loperamide is absorbed from the gut, but as a result of significant first pass

metabolism, systemic bioavailability is only approximately 0.3%.

Distribution: Studies on distribution in rats show a high affinity for the gut wall with a preference for

binding to receptors of the longitudinal muscle layer. The plasma protein binding of loperamide is 95%,

mainly to albumin. Non-clinical data have shown that loperamide is a P-glycoprotein substrate.

Biotransformation: Loperamide is almost completely extracted by the liver, where it is predominantly

metabolised, conjugated and excreted via the bile. Oxidative N-demethylation is the main metabolic

pathway for loperamide, and is mediated mainly through CYP3A4 and CYP2C8. Due to this very high

first pass effect, plasma concentrations of unchanged drug remain extremely low.

Elimination: The half-life of loperamide in man is about 11 hours with a range of 9-14 hours. Excretion of

the unchanged loperamide and the metabolites mainly occurs through the faeces.

Paediatric Population: No pharmacokinetic studies were performed in the paediatric population. It is

expected that pharmacokinetic behaviour of loperamide and drug-drug interactions with loperamide will

be similar to those in adults.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety

pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and

development.

Acute and chronic studies on loperamide showed no specific toxicity.

Loperamide had no effect on fertility in male rats when administered orally prior to mating at doses up to

approximately 40 mg/kg. No pregnancy occurred in females dosed with approximately 40 mg/kg. Lower

doses (approximately 10 and 2.5mg/kg) did not affect female fertility. In rabbits no differences in

pregnancy rate were observed when females were administered orally up to 40mg/kg.

No malformations of offspring were noted in rats and rabbits dosed up to 40 mg/kg. Loperamide did no

show genotoxic potential.

In an 18-month carcinogenicity study in rats, with doses up to 100 times the maximum human dose no

evidence of carcinogenesis was found.

Non-clinical in vitro and in vivo evaluation of loperamide indicates no significant cardiac

electrophysiological effects within its therapeutically relevant concentration range and at significant

multiples of this range (up to 47-fold. However, at extremely high concentrations associated with

overdoses (see section 4.4), loperamide has cardiac electrophysiological actions consisting of inhibition

of potassium (hERG) and sodium currents, and arrhythmias.

6. Pharmaceutical particulars

6.1 List of excipients

Capsules content:

Lactose monohydrate

Maize Starch

Talc

Magnesium Stearate

Capsules shell:

Titanium Dioxide (E171)

Gelatin

Printing Ink:

Shellac

Black Iron Oxide (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store below 30°C.

6.5 Nature and contents of container

Loperamide 2 mg hard capsules are available in clear PVC/Aluminium blisters pack.

Pack sizes:

Blister packs: 6, 8, 10, 12, 15, 18, 20, 30 & 50 hard capsules.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Milpharm Limited

Ares Block, Odyssey Business Park

West End Road

South Ruislip HA4 6QD

United Kingdom

8. Marketing authorisation number(s)

PL 16363/0534

9. Date of first authorisation/renewal of the authorisation

23/05/2018

10. Date of revision of the text

19/09/2019.

Company Contact Details

Aurobindo Pharma - Milpharm Ltd.

Address

Odyssey Business Park, Ares Block, West End Road, South Ruislip, Middlesex, HA4 6QD

Telephone

+ 44 (0)208 845 8811

Medical Information e-mail

[email

protected]

Medical Information Fax

+44 (0)208 845 8795

http://www.aurobindo.com

+44 (0)208 845 8735

Customer Care direct line

+44 (0)208 845 8811

Similar products

Search alerts related to this product

View documents history

Share this information